HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a price target of $9.
December 29, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics has been given a reiterated Buy rating and a maintained price target of $9 by HC Wainwright & Co. analyst Raghuram Selvaraju.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst typically instill confidence in current and potential investors, suggesting a positive outlook for the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100